"Niacin Doesn't Work and Is Harmful!" Proclaim the Headlines. Yet Another Highly Publicized Questionable Study to Discredit Integrative Medicine.
作者信息
Houston Mark, Pizzorno Joseph
出版信息
Integr Med (Encinitas). 2014 Oct;13(5):8-11.
Abstract
摘要
相似文献
1
"Niacin Doesn't Work and Is Harmful!" Proclaim the Headlines. Yet Another Highly Publicized Questionable Study to Discredit Integrative Medicine.
Integr Med (Encinitas). 2014 Oct;13(5):8-11.
2
New thinking on niacin use. Using niacin to raise "good" cholesterol doesn't lower your risk of having a heart attack or stroke.
Harv Health Lett. 2014 Aug;39(10):6.
3
"It just doesn't matter, it just doesn't matter, it just doesn't matter,...".
PDA J Pharm Sci Technol. 1998 Jul-Aug;52(4):149-50.
4
Clinical Inquiries: Does niacin decrease cardiovascular morbidity and mortality in CVD patients?
J Fam Pract. 2018 May;67(5):314-316.
5
Head Start doesn't work. What do you do when a beloved program doesn't produce results?
Time. 2011 Jul 18;178(3):27.
6
It doesn't have to be EviDense.
Hosp Pediatr. 2014 May;4(3):188-9. doi: 10.1542/hpeds.2014-0013.
7
The (Re) Production of the Genetically Related Body in Law, Technology and Culture: Mitochondria Replacement Therapy.
Health Care Anal. 2016 Sep;24(3):196-209. doi: 10.1007/s10728-016-0329-z.
8
9
If it doesn't work, stop it: medicine is a science of prediction and intervention.
BMJ. 2004 Apr 24;328(7446):1015; discussion 1016. doi: 10.1136/bmj.328.7446.1015-a.
10
What doesn't work and how to show it.
BMJ. 2004 Feb 28;328(7438):473. doi: 10.1136/bmj.328.7438.473.
引用本文的文献
1
Research Battles: Survival Tips From a Veteran.
Integr Med (Encinitas). 2015 Oct;14(5):30-2.
2
Issue 75!
Integr Med (Encinitas). 2015 Apr;14(2):8-13.
本文引用的文献
1
Effects of extended-release niacin with laropiprant in high-risk patients.
N Engl J Med. 2014 Jul 17;371(3):203-12. doi: 10.1056/NEJMoa1300955.
2
A high incidence of exanthematous eruption associated with niacin/laropiprant combination in Hong Kong Chinese patients.
J Clin Pharm Ther. 2013 Dec;38(6):528-32. doi: 10.1111/jcpt.12096. Epub 2013 Sep 10.
3
Inverse agonist and pharmacochaperone properties of MK-0524 on the prostanoid DP1 receptor.
PLoS One. 2013 Jun 10;8(6):e65767. doi: 10.1371/journal.pone.0065767. Print 2013.
4
The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression.
J Am Coll Cardiol. 2013 Jan 29;61(4):440-446. doi: 10.1016/j.jacc.2012.10.030. Epub 2012 Dec 19.
5
Effects of niacin on glucose levels, coronary stenosis progression, and clinical events in subjects with normal baseline glucose levels (<100 mg/dl): a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), HDL-Atherosclerosis Treatment Study (HATS), Armed Forces Regression Study (AFREGS), and Carotid Plaque Composition by MRI during lipid-lowering (CPC) study.
Am J Cardiol. 2013 Feb 1;111(3):352-5. doi: 10.1016/j.amjcard.2012.09.034. Epub 2012 Nov 17.
6
The facts behind niacin.
Ther Adv Cardiovasc Dis. 2011 Oct;5(5):227-40. doi: 10.1177/1753944711419197. Epub 2011 Sep 5.
7
Niacin: from mechanisms of action to therapeutic uses.
Mini Rev Med Chem. 2010 Mar;10(3):204-17. doi: 10.2174/138955710791185046.
8
Extended-release niacin or ezetimibe and carotid intima-media thickness.
N Engl J Med. 2009 Nov 26;361(22):2113-22. doi: 10.1056/NEJMoa0907569. Epub 2009 Nov 15.
9
Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study.
J Am Coll Cardiol. 2009 Nov 3;54(19):1787-94. doi: 10.1016/j.jacc.2009.06.036.
10
Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1.
Clin Pharmacol Ther. 2007 Jun;81(6):849-57. doi: 10.1038/sj.clpt.6100180. Epub 2007 Mar 28.
Zotero 插件